Effectiveness of Palonosetron, 1-Day Dexamethasone, and Aprepitant in Patients Undergoing Carboplatin-Based Chemotherapy
© 2023 S. Karger AG, Basel..
INTRODUCTION: Dexamethasone (DEX)-sparing strategy with 5-hydroxytryptamine-3 receptor antagonist (5HT3RA) and aprepitant (APR), as triplet antiemetic prophylaxis, is associated with poor control of delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving carboplatin (CBDCA)-based chemotherapy. This study aimed to evaluate whether using palonosetron (PALO) as a 5HT3RA provides superior control with CINV than first-generation (1st) 5HT3RA in triplet antiemetic prophylaxis with a DEX-sparing strategy.
METHODS: Pooled patient-level data from a nationwide, multicenter, and prospective observational study were analyzed to compare the incidence of CINV between patients administered PALO and 1st 5HT3RA in combination with 1-day DEX and APR.
RESULTS: No significant differences were observed in the incidence of CINV, pattern of CINV, or severity of nausea by type of 5HT3RA in triplet antiemetic prophylaxis with DEX-sparing strategy. In both groups, the incidence of nausea gradually increased from day 3, peaked on day 4 or 5, and then declined slowly. The visual analog scale scores in the delayed phase remained high throughout the 7-day observation period.
CONCLUSION: Careful patient selection and symptom monitoring are needed when implementing the DEX-sparing strategy in triplet antiemetic prophylaxis for patients undergoing CBDCA-based chemotherapy. Furthermore, additional strategies may be needed to achieve better control of delayed CINV.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:101 |
|---|---|
| Enthalten in: |
Oncology - 101(2023), 9 vom: 13., Seite 584-590 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hayashi, Toshinobu [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.09.2023 Date Revised 07.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1159/000531318 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357788060 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357788060 | ||
| 003 | DE-627 | ||
| 005 | 20231226073340.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000531318 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1192.xml |
| 035 | |a (DE-627)NLM357788060 | ||
| 035 | |a (NLM)37276851 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hayashi, Toshinobu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of Palonosetron, 1-Day Dexamethasone, and Aprepitant in Patients Undergoing Carboplatin-Based Chemotherapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.09.2023 | ||
| 500 | |a Date Revised 07.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 S. Karger AG, Basel. | ||
| 520 | |a INTRODUCTION: Dexamethasone (DEX)-sparing strategy with 5-hydroxytryptamine-3 receptor antagonist (5HT3RA) and aprepitant (APR), as triplet antiemetic prophylaxis, is associated with poor control of delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving carboplatin (CBDCA)-based chemotherapy. This study aimed to evaluate whether using palonosetron (PALO) as a 5HT3RA provides superior control with CINV than first-generation (1st) 5HT3RA in triplet antiemetic prophylaxis with a DEX-sparing strategy | ||
| 520 | |a METHODS: Pooled patient-level data from a nationwide, multicenter, and prospective observational study were analyzed to compare the incidence of CINV between patients administered PALO and 1st 5HT3RA in combination with 1-day DEX and APR | ||
| 520 | |a RESULTS: No significant differences were observed in the incidence of CINV, pattern of CINV, or severity of nausea by type of 5HT3RA in triplet antiemetic prophylaxis with DEX-sparing strategy. In both groups, the incidence of nausea gradually increased from day 3, peaked on day 4 or 5, and then declined slowly. The visual analog scale scores in the delayed phase remained high throughout the 7-day observation period | ||
| 520 | |a CONCLUSION: Careful patient selection and symptom monitoring are needed when implementing the DEX-sparing strategy in triplet antiemetic prophylaxis for patients undergoing CBDCA-based chemotherapy. Furthermore, additional strategies may be needed to achieve better control of delayed CINV | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antiemetics | |
| 650 | 4 | |a Carboplatin | |
| 650 | 4 | |a Chemotherapy-induced nausea and vomiting | |
| 650 | 4 | |a Dexamethasone | |
| 650 | 4 | |a Palonosetron | |
| 650 | 4 | |a Steroid-sparing | |
| 650 | 7 | |a Aprepitant |2 NLM | |
| 650 | 7 | |a 1NF15YR6UY |2 NLM | |
| 650 | 7 | |a Palonosetron |2 NLM | |
| 650 | 7 | |a 5D06587D6R |2 NLM | |
| 650 | 7 | |a Antiemetics |2 NLM | |
| 650 | 7 | |a Carboplatin |2 NLM | |
| 650 | 7 | |a BG3F62OND5 |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 650 | 7 | |a Isoquinolines |2 NLM | |
| 650 | 7 | |a Quinuclidines |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Shimokawa, Mototsugu |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuo, Koichi |e verfasserin |4 aut | |
| 700 | 1 | |a Uchiyama, Masanobu |e verfasserin |4 aut | |
| 700 | 1 | |a Kawada, Kei |e verfasserin |4 aut | |
| 700 | 1 | |a Nakano, Takafumi |e verfasserin |4 aut | |
| 700 | 1 | |a Egawa, Takashi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncology |d 1966 |g 101(2023), 9 vom: 13., Seite 584-590 |w (DE-627)NLM000043451 |x 1423-0232 |7 nnns |
| 773 | 1 | 8 | |g volume:101 |g year:2023 |g number:9 |g day:13 |g pages:584-590 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000531318 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 101 |j 2023 |e 9 |b 13 |h 584-590 | ||